Patents Assigned to DOMPÉ FARMACEUTICI S.P.A.
  • Publication number: 20220184009
    Abstract: Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.
    Type: Application
    Filed: February 24, 2022
    Publication date: June 16, 2022
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, DOMPE FARMACEUTICI S.P.A.
    Inventors: Paolo FIORINA, Roberto BASSI, Andrea VERGANI, Marcello ALLEGRETTI
  • Patent number: 11324630
    Abstract: A medical device (100) for the instillation of medical products in droplet form is described, said device comprising a hollow cylindrical body (10) and a rod (20) slidably mobile inside the hollow cylindrical body (10) and provided with a head (21) on which a rubber washer (40) is fixed, which washer, during the sliding of the rod (20), is in contact with an inner surface of the hollow cylindrical body (10). The rod (20) is formed as two portions (22, 24) of different diameter and the device (100) further comprises a sealing bush (30) between the hollow cylindrical body (10) and the rod (20), wherein there is provided a stop (32) which prevents the passage of the portion (22) with a larger circular section of the rod (20).
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: May 10, 2022
    Assignee: DOMPE' FARMACEUTICI S.P.A.
    Inventor: Alfredo Ricci
  • Patent number: 11291641
    Abstract: Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: April 5, 2022
    Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, DOMPE FARMACEUTICI S.P.A.
    Inventors: Paolo Fiorina, Roberto Bassi, Andrea Vergani, Marcello Allegretti
  • Patent number: 11236129
    Abstract: The invention relates to IL-17A binding peptides, inhibitors of the interaction of IL-17A with the receptor IL-17RA, and to bioconjugates, dimers, pharmaceutical compositions and medical use thereof.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: February 1, 2022
    Assignee: Dompe' Farmaceutici S.P.A.
    Inventors: Marcello Allegretti, Andrea Aramini, Andrea Beccari, Marica Gemei, Flavio Mantelli
  • Patent number: 11103379
    Abstract: The present invention relates to a device (1) for dispensing eye drops comprising a first container (2) containing water for injection (200) and a second container (3) containing a freeze-dried composition (300) comprising a drug. The first container (2) comprises a tubular element (9) with an open end portion (10) and the second container (3) comprises a wall (16) configured to be engaged in a fluid-tight manner around the tubular element (9) and a piercible barrier (17) which, in the assembled condition of the device (1), prevents mixing of the substances contained inside the first and second containers (2, 3). The drop dispensing device (1) also comprises a spacer (4) arranged between the first and second containers (2, 3); the spacer (4) does not allow the tubular element (9) to pierce the piercible barrier (17).
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: August 31, 2021
    Assignee: DOMPE' FARMACEUTICI S.P.A.
    Inventor: Marco Maria Gentile
  • Patent number: 11046662
    Abstract: The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). The compounds of the invention are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: June 29, 2021
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Andrea Aramini, Gianluca Bianchini, Laura Brandolini, Andrea Beccari, Samuele Lillini, Giuseppe Nano
  • Patent number: 10508090
    Abstract: The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I): Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GPR40 such as diabetes (particularly type 2 diabetes), impaired oral glucose tolerance, insulin resistance, obesity, obesity related disorders, metabolic syndrome, dyslipidemia, elevated LDL, elevated triglycerides, obesity induced inflammation, osteoporosis and obesity related cardiovascular disorders.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: December 17, 2019
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Maria De Pizzol, Anna Sirico, Mara Zippoli, Gianluca Bianchini, Andrea Beccari, Andrea Aramini, Chiara Rossana Maria Liberati
  • Patent number: 10442583
    Abstract: A process for the production of a device for dispensing eye drops. The process includes the steps of providing a first container and a second container configured to be engaged in a fluid-tight manner, providing a spacer, introducing a water-based solution inside the first container, introducing a solution or dispersion comprising a drug inside the second container, arranging the spacer between the first and second containers, engaging in a fluid-tight manner the second container and the first container, and freeze-drying the solution or dispersion comprising the drug.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: October 15, 2019
    Assignee: DOMPE' FARMACEUTICI S.P.A.
    Inventor: Marco Maria Gentile
  • Publication number: 20190224148
    Abstract: Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.
    Type: Application
    Filed: October 3, 2017
    Publication date: July 25, 2019
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, DOMPE FARMACEUTICI S.P.A.
    Inventors: Paolo FIORINA, Roberto BASSI, Andrea VERGANI, Marcello ALLEGRETTI
  • Patent number: 10246448
    Abstract: The invention relates to compounds acting as antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I): Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold-induced and/or exacerbated-respiratory disorders, urological disorders, corneal disorders associated to disturbances in the production of the tears and/or altered blinking such as epiphora and dry eye disease.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: April 2, 2019
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Andrea Aramini, Gianluca Bianchini, Samuele Lillini
  • Patent number: 10196368
    Abstract: The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: February 5, 2019
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Andrea Aramini, Gianluca Bianchini, Laura Brandolini, Andrea Beccari, Samuele Lillini, Giuseppe Nano
  • Patent number: 10010586
    Abstract: Nerve Growth Factor (NGF), in the form of a preparation to be administered over ocular surface, is suggested as being suitable for therapy and/or prophylaxis of intraocular tissue pathologies, with particular reference to sclera, ciliary body, crystalline lens, retina, optic nerve, vitreous body and choroidea affections. When administered in the form of external ophthlamic preparation, for example as collyrium or ointment, NGF is capable to go through ocular tissues and it has been found out that it shows a therapeutic activity not only against retina and optic nerve pathologies but also against affections involving the above reported internal structures of the eye.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: July 3, 2018
    Assignee: Dompé farmaceutici S.p.A.
    Inventor: Alessandro Lambiase
  • Publication number: 20180133053
    Abstract: The present invention relates to a device (1) for dispensing eye drops comprising a first container (2) containing water for injection (200) and a second container (3) containing a freeze-dried composition (300) comprising a drug. The first container (2) comprises a tubular element (9) with an open end portion (10) and the second container (3) comprises a wall (16) configured to be engaged in a fluid-tight manner around the tubular element (9) and a piercible barrier (17) which, in the assembled condition of the device (1), prevents mixing of the substances contained inside the first and second containers (2, 3). The drop dispensing device (1) also comprises a spacer (4) arranged between the first and second containers (2, 3); the spacer (4) does not allow the tubular element (9) to pierce the piercible barrier (17).
    Type: Application
    Filed: April 7, 2016
    Publication date: May 17, 2018
    Applicant: DOMPE' FARMACEUTICI S.P.A.
    Inventor: Marco Maria Gentile
  • Patent number: 9856246
    Abstract: The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula: Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: January 2, 2018
    Assignee: Dompé farmaceutici S.p.A.
    Inventors: Alessio Moriconi, Gianluca Bianchini, Sandro Colagioia, Laura Brandolini, Andrea Aramini, Chiara Liberati, Silvia Bovolenta
  • Patent number: 9585875
    Abstract: The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exhacerbated respiratory disorders and urological disorders.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: March 7, 2017
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Alessio Moriconi, Gianluca Bianchini, Sandro Colagioia, Laura Brandolini, Andrea Aramini, Chiara Liberati, Silvia Bovolenta
  • Patent number: 9556115
    Abstract: The use of sulfonamides of formula (I) wherein R and R1 are as defined in the description, for the preparation of medicaments for the prevention of diabetes, in particular of type-1 diabetes is herein disclosed.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: January 31, 2017
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Lorenzo Piemonti, Luisa Daffonchio, Marcello Allegretti
  • Patent number: 9493402
    Abstract: (R)-2-Arylpropionamide compounds of formula (I), pharmaceutical preparations of the compounds and a process for making the compounds are described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonuclear leukocytes and monocytes at inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use as inhibitors of chemotaxis of neutrophils and monocytes induced by the C5a fraction of complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of neutrophils and monocytes and the IL-8-induced chemotaxis of polymorphonuclear leukocytes.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: November 15, 2016
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Marcello Allegretti, Riccardo Bertini, Valerio Berdini, Cinzia Bizzarri, Maria Candida Cesta, Vito Di Cioccio, Gianfranco Caselli, Francesco Colotta, Carmelo Gandolfi
  • Patent number: 9468665
    Abstract: Nerve Growth Factor (NGF), in the form of a preparation to be administered over ocular surface, is suggested as being suitable for therapy and/or prophylaxis of intraocular tissue pathologies, with particular reference to sclera, ciliary body, crystalline lens, retina, optic nerve, vitreous body and choroidea affections. When administered in the form of external ophthalmic preparation, for example as collyrium or ointment, NGF is capable to go through ocular tissues and it has been found out that it shows a therapeutic activity not only against retina and optic nerve pathologies but also against affections involving the above reported internal structures of the eye.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: October 18, 2016
    Assignee: Dompé Farmaceutici S.p.A.
    Inventor: Alessandro Lambiase
  • Patent number: 9409876
    Abstract: The present invention relates to compounds represented by formula (I) and pharmaceutically acceptable salts thereof that are antagonists of the bradykinin B1 receptor. These compounds are useful for the treatment of disorders associated with the bradykinin B1 pathway, in particular pain-related disorders.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: August 9, 2016
    Assignee: DOMPE' FARMACEUTICI S.P.A.
    Inventors: Andrea Rosario Beccari, Gianluca Bianchini, Chiara Liberati, Michela Fani', Mara Zippoli
  • Patent number: 9345749
    Abstract: Nerve Growth Factor (NGF), in the form of a preparation to be administered over ocular surface, is suggested as being suitable for therapy and/or prophylaxis of intraocular tissue pathologies, with particular reference to sclera, ciliary body, crystalline lens, retina, optic nerve, vitreous body and choroidea affections. When administered in the form of external ophthalmic preparation, for example as collyrium or ointment, NGF is capable to go through ocular tissues and it has been found out that it shows a therapeutic activity not only against retina and optic nerve pathologies but also against affections involving the above reported internal structures of the eye.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: May 24, 2016
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventor: Alessandro Lambiase